Approved HIV Drugs
Approved HIV Drugs
Atazanavir Associated with Less HIV Treatment Failure, Illness, and Death
- Details
- Category: Approved HIV Drugs
- Published on Wednesday, 11 February 2015 00:00
- Written by Liz Highleyman
People with HIV who used antiretroviral regimens containing the ritonavir-boosted protease inhibitor atazanavir (Reyataz) had better outcomes than those taking lopinavir/ritonavir (Kaletra), including lower likelihood of AIDS-defining illnesses or death, less virological failure, and larger CD4 T-cell increases, according to a study published in the January 6 edition of Clinical Infectious Diseases.
FDA Approves 2 New Boosted Protease Inhibitor Coformulations for HIV
- Details
- Category: Approved HIV Drugs
- Published on Friday, 30 January 2015 00:00
- Written by HIVandHepatitis.com
The U.S. Food and Drug Administration (FDA) this week approved 2 new fixed-dose coformulations of HIV protease inhibitors with a cobicistat booster. Bristol-Myers Squibb's Evotaz contains atazanavir (sold separately as Reyataz) plus cobicistat, while Janssen Therapeutics' Prezcobix contains darunavir (sold separately as Prezista) plus cobicistat.
HIV Drug Therapy: Lower-dose Efavirenz Equally Effective with Fewer Side Effects
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 23 December 2014 00:00
- Written by Liz Highleyman
A reduced dose of efavirenz (Sustiva or Stocrin) for first-line HIV therapy suppressed viral load as well as the standard dose, but was associated with fewer characteristic side effects, researchers reported at the recent HIV Drug Therapy 2014 meeting in Glasgow. A related study found that half the dose maintained viral suppression in people with high efavirenz levels in their blood.
6. HIV Drugs: Few New Approvals, but Pipeline Looks Promising
- Details
- Category: Approved HIV Drugs
- Published on Monday, 12 January 2015 00:00
- Written by HIVandHepatitis.com
HIV drug development news in 2014 included approval of a new single-tablet regimen and 2 more components of antiretroviral therapy (ART). Promising candidates in the pipeline include a better-tolerated version of tenofovir, a NNRTI with fewer neuropsychiatric side effects, and potential long-acting injectables that may be useful for treatment or pre-exposure prophylaxis.
HIV Drug Therapy: Efavirenz Not Linked to Higher Suicide Risk in D:A:D Cohort
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 09 December 2014 00:00
- Written by Liz Highleyman
People taking antiretroviral therapy (ART) regimens containing the NNRTI efavirenz (Sustiva) were not more likely to die due to suicide or psychiatric illness than those taking other drugs in the large D:A:D cohort, researchers reported last month at the HIV Drug Therapy 2014 meeting in Glasgow.
More Articles...
- HIV Drug Therapy: Once-daily Dolutegravir Superior to Darunavir at 96 Weeks
- HIV Drug Therapy: Darunavir/Ritonavir Protease Inhibitor Monotherapy Less Effective than 3-Drug ART
- HIV Drug Therapy: Do Emtricitabine and Lamivudine Have Similar Efficacy for First-line ART?
- HIV Drug Therapy: Efavirenz Compromises Hormonal Contraceptive Implant
Web Design and Development by